S
Seho Park
Researcher at Yonsei University
Publications - 185
Citations - 3719
Seho Park is an academic researcher from Yonsei University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 30, co-authored 154 publications receiving 3027 citations. Previous affiliations of Seho Park include Washington University in St. Louis.
Papers
More filters
Journal ArticleDOI
Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry
Seho Park,Ja Seung Koo,Min Suk Kim,Hyung Seok Park,Jun Sang Lee,Jong Seok Lee,Seung Il Kim,Byeong Woo Park +7 more
TL;DR: Molecular subtypes using four biomarkers could provide clinically useful information of tumor biology and clinical behaviors, and could be used for determining treatment and surveillance strategies.
Journal ArticleDOI
Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers
Seho Park,Ja Seung Koo,Myeong-Kyu Kim,Hyung Seok Park,Jun Sang Lee,Seung Il Kim,Byeong Woo Park,Kyung-Eun Lee +7 more
TL;DR: The results suggest that AR could be an additional marker for endocrine responsiveness in ER-positive cancers and a candidate for therapeutic targeting of ER-negative tumors.
Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.
Seho Park,Ja Seung Koo,Myeong-Kyu Kim,Hyung Seok Park,Jun Sang Lee,Seung Il Kim,Byeong Woo Park,Kyung-Eun Lee +7 more
TL;DR: In this paper, the implications of androgen receptor (AR) in breast cancers were evaluated using uni-/multivariate analyses. And the results suggest that AR could be an additional marker for endocrine responsiveness in ER-positive cancers and a candidate for therapeutic targeting of ER-negative tumors.
Journal ArticleDOI
Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes
TL;DR: High preoperative CA 15-3 and CEA levels may reflect tumor burden and are associated with advanced disease and poor outcome, and can be helpful for predicting outcomes.
Journal ArticleDOI
S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.
Yong Wha Moon,Yong Wha Moon,Soohyeon Lee,Byeong Woo Park,Eun Kyung Kim,Seung Il Kim,Ja Seung Koo,Seho Park,Min Jung Kim,Hyun Cheol Chung,Joo Hang Kim,Joohyuk Sohn +11 more
TL;DR: Given all axillary lymph node positive diseases, neoadjuvant S-1 combined with docetaxel following AC showed a favorable anti-tumor activity but gastrointestinal discomfort should be carefully considered for future studies.